Ezetimibe and Statin-Associated Myopathy
Authors: Paul S. Phillips
Journal: Annals of Internal Medicine (2004)

Letters19 October 2004Ezetimibe and Statin-Associated MyopathyPaul S. Phillips, MDPaul S. Phillips, MDFrom Scripps Mercy Hospital, San Diego, CA 92103.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-141-8-200410190-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The letter by Fux and colleagues (1) suggesting an interaction between ezetimibe and statin-associated myopathy confirms our own findings. It is known that most lipid-lowering therapies, including statins, fibrates, and niacin, may cause muscle toxicity. The common feature of these therapies is that they reduce levels of triglycerides and free fatty acids. Hypertriglyceridemia is common among patients with reactions to lipid-lowering therapies (2), some of whom may have defects in fatty acid oxidation (3). Respiratory exchange ratios have been used to identify abnormalities in fatty acid oxidation (4). The fasting respiratory exchange ratio is increased in patients ...References1. Fux R, Morike K, Gundel UF, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy [Letter]. Ann Intern Med. 2004;140:671-2. [PMID: 15096354] LinkGoogle Scholar2. Kordas KC, Phillips PS, Golomb BA. Clinical characteristics of 1053 patients with statin associated muscle complaints [Abstract]. Arterioscler Thromb Vasc Biol. 2004;24:51-e136. Google Scholar3. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160-8. [PMID: 8100834] CrossrefMedlineGoogle Scholar4. Carroll JE, Brooke MH, DeVivo DC, Kaiser KK, Hagberg JM. Biochemical and physiologic consequences of carnitine palmityltransferase deficiency. Muscle Nerve. 1978;1:103-10. [PMID: 750917] CrossrefMedlineGoogle Scholar5. Phillips CT, Gray NL, Puhek LM, McDonald FG, Sullivan MJ, Phillips PS. Cardiopulmonary function is abnormal after statin-induced rhabdomyolysis and myositis [Abstract]. J Am Coll Cardiol. 2004;43 Suppl A 16a. CrossrefGoogle Scholar6. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al . Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-5. [PMID: 12353945] LinkGoogle Scholar7. Phillips CT, Gray NL, Puhek LM, McDonald FG, Sullivan MJ, Phillips PS. Basal respiratory exchange ratio is altered with statin use in normals [Abstract]. J Am Coll Cardiol. 2004;43 Suppl A 233a. CrossrefGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Scripps Mercy Hospital, San Diego, CA 92103. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoStatin-Associated Myopathy with Normal Creatine Kinase Levels Paul S. Phillips , Richard H. Haas , Sergei Bannykh , Stephanie Hathaway , Nancy L. Gray , Bruce J. Kimura , Georgirene D. Vladutiu , John D.F. England , and Ezetimibe and Statin-Associated Myopathy Richard Fux , Klaus Mörike , Udo-Frank Gundel , Rüdiger Hartmann , and Christoph H. Gleiter Metrics Cited ByEffects of a Portfolio-Mediterranean Diet and a Mediterranean Diet with or without a Sterol-Enriched Yogurt in Individuals with HypercholesterolemiaPCSK9 inhibition for LDL lowering and beyond – implications for patients with peripheral artery diseaseAtorvastatinEzetimibeStatin induced myotoxicityEzetimibe-induced Relapsing Polymyositis: Table 1Drugs that affect lipid metabolismBalancing Randomized Trials With AnecdotePaul S. Phillips, MDLIPID – REGULATING DRUGSEzetimibe-related myopathy: A systematic reviewA Neuromuscular Approach to Statin-Related MyotoxicityEzetimibe-associated adverse effects: what the clinician needs to knowSafety Considerations with Gastrointestinally Active Lipid-Lowering DrugsExpert Commentary: Gastrointestinally Active Lipid-Lowering Drug SafetyMyopathy Associated with Atorvastatin-Ezetimibe Combination Therapy44 Drugs that affect lipid metabolismNon-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overviewStatin myopathy: an updateElevation of CKP induced by ezetimibe in monotherapyCombination therapy with ezetimibe and simvastatin to achieve aggressive LDL reductionClinical Perspectives of Statin-Induced RhabdomyolysisStatin Safety: An Overview and Assessment of the Data—2005Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibeEzetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorReply 19 October 2004Volume 141, Issue 8Page: 649KeywordsAcidsExcretionExercise therapyFatty acidsMuscle biopsiesMusclesNiacinPharmacokineticsStatinsToxicity ePublished: 19 October 2004 Issue Published: 19 October 2004 CopyrightCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...